Biotech & Pharma

Rewriting Disease: Oligonucleotides Take Aim at the Untreatable

25 sec read32 views0 listens

Oligonucleotide therapeutics are emerging as a powerful new approach in drug discovery, targeting previously undruggable disease-causing genes by altering RNA and gene-regulatory pathways. This technology is advancing with the help of AI and multiomics analysis, enabling precise identification of patient subgroups likely to benefit from specific therapies and uncovering novel targets for conditions like neurodegeneration and fibrosis.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

CybersecurityJun 732 sec read

The side effects no one reported: How Reddit and AI are changing drug safety

Researchers at the University of Pennsylvania are utilizing large language models to analyze over 400,000 Reddit posts to identify previously unreported side effects of GLP-1 weight-loss drugs. This demonstrates the growing utility of AI in processin...

Ali Nemati

Health & Medicine2 days ago29 sec read

STAT+: Pharmalittle: We're reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more

Regeneron Pharmaceuticals has received U.S. regulatory approval for Pasatru, a drug aimed at treating fibrodysplasia ossificans progressiva (FOP), a rare disease causing abnormal bone growth. Separately, Ultragenyx Pharmaceutical’s gene therapy Gengl...

Ali Nemati

Health & Medicine3 days ago25 sec read

STAT+: Pharmalittle: We're reading about an FDA commish nominee, mRNA cancer vaccine results, and more

President Trump is expected to nominate Heidi Overton, a key health policy advisor in his administration, as the next FDA commissioner. Additionally, a late-stage clinical trial shows that a personalized mRNA cancer vaccine, when combined with existi...

Ali Nemati